Asclep Pharma

Confidentiality Agreement

The undersigned reader acknowledges that the information provided by _______________ in this

business plan is confidential; therefore, reader agrees not to disclose it without the express written

permission of _______________.

It is acknowledged by reader that information to be furnished in this business plan is in all respects

confidential in nature, other than information which is in the public domain through other means and

that any disclosure or use of same by reader, may cause serious harm or damage to

_______________.

Upon request, this document is to be immediately returned to _______________.

___________________

Signature

___________________

Name (typed or printed)

___________________

Date

This is a business plan. It does not imply an offering of securities.

Table of Contents

Page 1

1.0 Executive Summary ......................................................................................................................................1

Chart: Highlights ..............................................................................................................................1

1.1 Objectives ...........................................................................................................................................1

1.2 Mission ................................................................................................................................................1

1.3 Keys to Success..................................................................................................................................1

2.0 Company Summary ......................................................................................................................................2

2.1 Company Ownership ..........................................................................................................................2

2.2 Start-up Summary ...............................................................................................................................2

Table: Start-up .................................................................................................................................2

Chart: Start-up .................................................................................................................................3

3.0 Products ........................................................................................................................................................3

4.0 Market Analysis Summary ............................................................................................................................3

4.1 Market Segmentation ..........................................................................................................................3

Table: Market Analysis ....................................................................................................................4

Chart: Market Analysis (Pie) ...........................................................................................................4

4.2 Target Market Segment Strategy .......................................................................................................4

4.3 Industry Analysis .................................................................................................................................4

4.3.1 Competition and Buying Patterns ..........................................................................................4

5.0 Strategy and Implementation Summary .......................................................................................................5

5.1 SWOT Analysis ...................................................................................................................................5

5.1.1 Strengths ................................................................................................................................5

5.1.2 Weaknesses ..........................................................................................................................5

5.1.3 Opportunities ..........................................................................................................................5

5.1.4 Threats ...................................................................................................................................5

5.2 Competitive Edge ................................................................................................................................5

5.3 Marketing Strategy ..............................................................................................................................5

5.4 Sales Strategy .....................................................................................................................................6

5.4.1 Sales Forecast .......................................................................................................................6

Table: Sales Forecast ...........................................................................................................6

Chart: Sales Monthly .............................................................................................................6

Chart: Sales by Year .............................................................................................................7

5.5 Milestones ...........................................................................................................................................7

Table: Milestones ............................................................................................................................7

Chart: Milestones ............................................................................................................................8

6.0 Management Summary ................................................................................................................................8

6.1 Personnel Plan ....................................................................................................................................9

Table: Personnel .............................................................................................................................9

7.0 Financial Plan ...............................................................................................................................................9

7.1 Start-up Funding .................................................................................................................................9

Table: Start-up Funding ................................................................................................................10

7.2 Important Assumptions .....................................................................................................................10

7.3 Break-even Analysis .........................................................................................................................10

Table: Break-even Analysis ..........................................................................................................10

Chart: Break-even Analysis ...........................................................................................................11

7.4 Projected Profit and Loss ..................................................................................................................11

Table: Profit and Loss ...................................................................................................................12

Chart: Profit Monthly .....................................................................................................................12

Chart: Profit Yearly ........................................................................................................................13

Chart: Gross Margin Monthly ........................................................................................................13

Chart: Gross Margin Yearly...........................................................................................................14

7.5 Projected Cash Flow .........................................................................................................................14

Table: Cash Flow ..........................................................................................................................15

Chart: Cash ...................................................................................................................................16

Table of Contents

Page 2

7.6 Projected Balance Sheet ..................................................................................................................16

Table: Balance Sheet ....................................................................................................................17

7.7 Business Ratios ................................................................................................................................17

Table: Ratios .................................................................................................................................18

Table: Sales Forecast .........................................................................................................................................1

Table: Personnel .................................................................................................................................................2

Table: Profit and Loss .........................................................................................................................................3

Table: Cash Flow ................................................................................................................................................4

Table: Balance Sheet .........................................................................................................................................5

ASCLEP PHARMA

Page 1

1.0 Executive Summary

1.1 Objectives

1. To deliver the medicines and surgical supplies to the retailers such us hospitals , clinics

and medical shops .

2. To establish ourself as a premier pharmaceutical distributing company by 2020

1.2 Mission

ASCLEP Pharma offers pharmaceutical , biotechnological and medical device manufactures a

reliable , high quality alternative way for sales and marketing of the products. ASCLEP pharma

improves the return on sales and marketing investment by accelerating the physician learning curve

on prelaunch, new, and existing products. In addition,ASCLEP will benefit small and innovative

biotechnology and pharmaceutical companies that do not have an extensive sales force to cover

Kerala especially in southern districts like Trivandrum, Kollam,Pathanamthitta. Alappuzha &

Kottayam.

1.3 Keys to Success

ASCLEP PHARMA

Page 2

2.0 Company Summary

ASCLEP Pharma is a pharamaceutical Distribution Company which is providing high level expertise

in the marketing and selling of pharmaceutical products. The company's headquarters is in

Pathanamthitta Kerala India

2.1 Company Ownership

ASCLEP Pharma is under mutual partnership of

1. Dr Hassan Mohammed Aziz

2. Mr Arun Kumar MJ

3. Mr Shameer A

4. Mr Fayush Yonus

Each of the share holders holds 25% of shares of the company and the profit share of each share

holder is 25% of total net profit.

2.2 Start-up Summary

The table below illustrates a complete breakdown of all start-up assets that are needed, as total

start-up requirements. Currently, we have no short-term liabilities.

Table: Start-up

Start-up

Requirements

Start-up Expenses

Legal $30,000

Stationery $5,000

Insurance $10,000

Rent $10,000

Other $10,000

Total Start-up Expenses $65,000

Start-up Assets

Cash Required $100,000

Start-up Inventory $200,000

Other Current Assets $0

Long-term Assets $0

Total Assets $300,000

Total Requirements $365,000

ASCLEP PHARMA

Page 3

3.0 Products

The products that ASCLEP Pharma offers

1. Medicines

2. Medical Equipments

3. Surgical Instruments

4.0 Market Analysis Summary

Currently, the largest market segment is the pharmaceutical industry. We have a huge opportunity

in this segment. ASCLEP Pharma is fully concenterated in Hospitals Clinics and Medical shops in

southern districts of Kerala such as Pathanamthitta , Kollam, Thiruvananthapuram , Alappuzha &

Kottayam in the first two years and we will extend the demographics regions such

as Ernakulam , Thrissur, Koazhikode & Malappuram .

Before 2020 we will acquire the distribution for all demographics regions of the Kerala.

4.1 Market Segmentation

Conduct the Market Study??????????????????????????????????

ASCLEP PHARMA

Page 4

Table: Market Analysis

Market Analysis

Year 1 Year 2 Year 3 Year 4 Year 5

Potential Customers Growth CAGR

Hospitals 50% 20 30 45 68 102 50.28%

Clinics 50% 25 38 57 86 129 50.72%

Medical Shops 50% 100 150 225 338 507 50.06%

Total 50.20% 145 218 327 492 738 50.20%

4.2 Target Market Segment Strategy

Conduct Study ....................Discuss with Partners

Dr Hassan 's PART

4.3 Industry Analysis

To be analysed......................................

4.3.1 Competition and Buying Patterns

Buying Patterns ......Competitions ..................To Be Analaysed .....

Primary data

Pathanamthitta

ASCLEP PHARMA

Page 5

1. MALANADU PHARMACEUTICALS

Kozhencherry, Pathanamthitta

2. M/S Suraj Pharma

Thiruvalla, Pathanamthitta

3. Samsons

Kozhencherry, Pathanamthitta

4. Pharma Traders


5. M M Drug Links


5.0 Strategy and Implementation Summary

5.1 SWOT Analysis

Have a chat with partners..................

5.1.1 Strengths


5.1.2 Weaknesses


5.1.3 Opportunities


5.1.4 Threats


5.2 Competitive Edge


5.3 Marketing Strategy



ASCLEP PHARMA

Page 6

5.4 Sales Strategy

To be Checked with Hassan ..................

5.4.1 Sales Forecast

Table: Sales Forecast

Sales Forecast

Year 1 Year 2 Year 3

Sales

Medicines $300,000 $450,000 $600,000

Surgical Instruments $300,000 $450,000 $600,000

Total Sales $600,000 $900,000 $1,200,000

Direct Cost of Sales Year 1 Year 2 Year 3

Cost of Goods Medicines $180,000 $270,000 $405,000

Cost of Goods Surgical Supplies $180,000 $270,000 $405,000

Transportation Costs $60,000 $90,000 $120,000

Subtotal Direct Cost of Sales $420,000 $630,000 $930,000

ASCLEP PHARMA

Page 7

5.5 Milestones


Table: Milestones

Milestones

Milestone Start Date End Date Budget Manager Department

Name me 5/8/2015 6/7/2015 $0 ABC Department










Totals $0

ASCLEP PHARMA

Page 8

6.0 Management Summary

ASCLEP Pharma is a Parnership firm formed by 4 partners who are excelled in four different

segments.

1 DR Hassan Mohammed Aziz MBBS

Chairman of the company who is a graduate in medical science , practicing as a Junior Doctor in

various hospitals. He posses the Head of Marketing department of the company

2 Mr Fayush Yonus MBA

Managing Director of the company who is graduated in human resourse and marketing, worked

as Administration Manager in UAE and as credit officer in Standard Chartered Bank India.

3 Mr Arun Kumar MJ BCom

Head of Finance Department of the company,who have an immense experience in accounting and

banking sector ,wo

4 Mr Shameer A NeBosh

Head of HR department , who have an immense experience in EMAAR Group ,Dubai ,UAE

ASCLEP PHARMA

Page 9

6.1 Personnel Plan

Table: Personnel

Personnel Plan


HR Department $0 $0 $0

Finanace Department $0 $0 $0

Marketing Department $0 $0 $0

Total People 0 0 0

Total Payroll $0 $0 $0

7.0 Financial Plan

7.1 Start-up Funding

ASCLEP PHARMA

Page 10

Table: Start-up Funding

Start-up Funding

Start-up Expenses to Fund $65,000

Start-up Assets to Fund $300,000

Total Funding Required $365,000

Assets

Non-cash Assets from Start-up $200,000

Cash Requirements from Start-up $100,000

Additional Cash Raised $0

Cash Balance on Starting Date $100,000

Total Assets $300,000

Liabilities and Capital

Liabilities

Current Borrowing $0

Long-term Liabilities $0

Accounts Payable (Outstanding Bills) $0

Other Current Liabilities (interest-free) $0

Total Liabilities $0

Capital

Planned Investment

Owner $0

Investor $0

Additional Investment Requirement $365,000

Total Planned Investment $365,000

Loss at Start-up (Start-up Expenses) ($65,000)

Total Capital $300,000

Total Capital and Liabilities $300,000

Total Funding $365,000

7.2 Important Assumptions

7.3 Break-even Analysis

Table: Break-even Analysis

Break-even Analysis

Monthly Revenue Break-even $0

Assumptions:

Average Percent Variable Cost 70%

Estimated Monthly Fixed Cost $0

ASCLEP PHARMA

Page 11

7.4 Projected Profit and Loss

ASCLEP PHARMA

Page 12

Table: Profit and Loss

Pro Forma Profit and Loss


Sales $600,000 $900,000 $1,200,000

Direct Cost of Sales $420,000 $630,000 $930,000

Other Costs of Sales $0 $0 $0

Total Cost of Sales $420,000 $630,000 $930,000

Gross Margin $180,000 $270,000 $270,000

Gross Margin % 30.00% 30.00% 22.50%

Expenses

Payroll $0 $0 $0

Marketing/Promotion $0 $0 $0

Depreciation $0 $0 $0

Rent $0 $0 $0

Utilities $0 $0 $0

Insurance $0 $0 $0

Payroll Taxes $0 $0 $0

Other $0 $0 $0

Total Operating Expenses $0 $0 $0

Profit Before Interest and Taxes $180,000 $270,000 $270,000

EBITDA $180,000 $270,000 $270,000

Interest Expense $0 $0 $0

Taxes Incurred $54,000 $81,000 $81,000

Net Profit $126,000 $189,000 $189,000

Net Profit/Sales 21.00% 21.00% 15.75%

ASCLEP PHARMA

Page 13

ASCLEP PHARMA

Page 14

7.5 Projected Cash Flow

ASCLEP PHARMA

Page 15

Table: Cash Flow

Pro Forma Cash Flow


Cash Received

Cash from Operations

Cash Sales $600,000 $900,000 $1,200,000

Subtotal Cash from Operations $600,000 $900,000 $1,200,000

Additional Cash Received

Sales Tax, VAT, HST/GST Received $0 $0 $0

New Current Borrowing $0 $0 $0

New Other Liabilities (interest-free) $0 $0 $0

New Long-term Liabilities $0 $0 $0

Sales of Other Current Assets $0 $0 $0

Sales of Long-term Assets $0 $0 $0

New Investment Received $0 $0 $0

Subtotal Cash Received $600,000 $900,000 $1,200,000

Expenditures Year 1 Year 2 Year 3

Expenditures from Operations

Cash Spending $0 $0 $0

Bill Payments $349,650 $784,831 $1,088,958

Subtotal Spent on Operations $349,650 $784,831 $1,088,958

Additional Cash Spent

Sales Tax, VAT, HST/GST Paid Out $0 $0 $0

Principal Repayment of Current Borrowing $0 $0 $0

Other Liabilities Principal Repayment $0 $0 $0

Long-term Liabilities Principal Repayment $0 $0 $0

Purchase Other Current Assets $0 $0 $0

Purchase Long-term Assets $0 $0 $0

Dividends $0 $0 $0

Subtotal Cash Spent $349,650 $784,831 $1,088,958

Net Cash Flow $250,350 $115,169 $111,042

Cash Balance $350,350 $465,519 $576,561

ASCLEP PHARMA

Page 16

7.6 Projected Balance Sheet

ASCLEP PHARMA

Page 17

Table: Balance Sheet

Pro Forma Balance Sheet


Assets

Current Assets

Cash $350,350 $465,519 $576,561

Inventory $80,000 $219,375 $318,699

Other Current Assets $0 $0 $0

Total Current Assets $430,350 $684,894 $895,260

Long-term Assets

Long-term Assets $0 $0 $0

Accumulated Depreciation $0 $0 $0

Total Long-term Assets $0 $0 $0

Total Assets $430,350 $684,894 $895,260

Liabilities and Capital Year 1 Year 2 Year 3

Current Liabilities

Accounts Payable $4,350 $69,894 $91,260

Current Borrowing $0 $0 $0

Other Current Liabilities $0 $0 $0

Subtotal Current Liabilities $4,350 $69,894 $91,260

Long-term Liabilities $0 $0 $0

Total Liabilities $4,350 $69,894 $91,260

Paid-in Capital $365,000 $365,000 $365,000

Retained Earnings ($65,000) $61,000 $250,000

Earnings $126,000 $189,000 $189,000

Total Capital $426,000 $615,000 $804,000

Total Liabilities and Capital $430,350 $684,894 $895,260

Net Worth $426,000 $615,000 $804,000

7.7 Business Ratios

ASCLEP PHARMA

Page 18

Table: Ratios

Ratio Analysis

Year 1 Year 2 Year 3 Industry Profile

Sales Growth n.a. 50.00% 33.33% 0.00%

Percent of Total Assets

Inventory 18.59% 32.03% 35.60% 0.00%

Other Current Assets 0.00% 0.00% 0.00% 100.00%

Total Current Assets 100.00% 100.00% 100.00% 100.00%

Long-term Assets 0.00% 0.00% 0.00% 0.00%

Total Assets 100.00% 100.00% 100.00% 100.00%

Current Liabilities 1.01% 10.21% 10.19% 0.00%

Long-term Liabilities 0.00% 0.00% 0.00% 0.00%

Total Liabilities 1.01% 10.21% 10.19% 0.00%

Net Worth 98.99% 89.79% 89.81% 100.00%

Percent of Sales

Sales 100.00% 100.00% 100.00% 100.00%

Gross Margin 30.00% 30.00% 22.50% 0.00%

Selling, General & Administrative Expenses 9.00% 9.00% 6.75% 0.00%

Advertising Expenses 0.00% 0.00% 0.00% 0.00%

Profit Before Interest and Taxes 30.00% 30.00% 22.50% 0.00%

Main Ratios

Current 98.93 9.80 9.81 0.00

Quick 80.54 6.66 6.32 0.00

Total Debt to Total Assets 1.01% 10.21% 10.19% 0.00%

Pre-tax Return on Net Worth 42.25% 43.90% 33.58% 0.00%

Pre-tax Return on Assets 41.83% 39.42% 30.16% 0.00%

Additional Ratios Year 1 Year 2 Year 3

Net Profit Margin 21.00% 21.00% 15.75% n.a

Return on Equity 29.58% 30.73% 23.51% n.a

Activity Ratios

Inventory Turnover 4.31 4.21 3.46 n.a

Accounts Payable Turnover 81.38 12.17 12.17 n.a

Payment Days 27 16 26 n.a

Total Asset Turnover 1.39 1.31 1.34 n.a

Debt Ratios

Debt to Net Worth 0.01 0.11 0.11 n.a

Current Liab. to Liab. 1.00 1.00 1.00 n.a

Liquidity Ratios

Net Working Capital $426,000 $615,000 $804,000 n.a

Interest Coverage 0.00 0.00 0.00 n.a

Additional Ratios

Assets to Sales 0.72 0.76 0.75 n.a

Current Debt/Total Assets 1% 10% 10% n.a

Acid Test 80.54 6.66 6.32 n.a

Sales/Net Worth 1.41 1.46 1.49 n.a

Dividend Payout 0.00 0.00 0.00 n.a

Appendix

Page 1

Table: Sales Forecast

Sales Forecast

Month 1 Month 2 Month 3 Month 4 Month 5 Month 6 Month 7 Month 8 Month 9 Month 10 Month 11 Month 12

Sales

Medicines $25,000 $25,000 $25,000 $25,000 $25,000 $25,000 $25,000 $25,000 $25,000 $25,000 $25,000 $25,000

Surgical Instruments $25,000 $25,000 $25,000 $25,000 $25,000 $25,000 $25,000 $25,000 $25,000 $25,000 $25,000 $25,000

Total Sales $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000

Direct Cost of Sales Month 1 Month 2 Month 3 Month 4 Month 5 Month 6 Month 7 Month 8 Month 9 Month 10 Month 11 Month 12

Cost of Goods Medicines $15,000 $15,000 $15,000 $15,000 $15,000 $15,000 $15,000 $15,000 $15,000 $15,000 $15,000 $15,000

Cost of Goods Surgical Supplies $15,000 $15,000 $15,000 $15,000 $15,000 $15,000 $15,000 $15,000 $15,000 $15,000 $15,000 $15,000

Transportation Costs $5,000 $5,000 $5,000 $5,000 $5,000 $5,000 $5,000 $5,000 $5,000 $5,000 $5,000 $5,000

Subtotal Direct Cost of Sales $35,000 $35,000 $35,000 $35,000 $35,000 $35,000 $35,000 $35,000 $35,000 $35,000 $35,000 $35,000

Appendix

Page 2

Table: Personnel

Personnel Plan


HR Department $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0

Finanace Department $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0

Marketing Department $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0

Total People 0 0 0 0 0 0 0 0 0 0 0 0

Total Payroll $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0

Appendix

Page 3

Table: Profit and Loss

Pro Forma Profit and Loss


Sales $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000

Direct Cost of Sales $35,000 $35,000 $35,000 $35,000 $35,000 $35,000 $35,000 $35,000 $35,000 $35,000 $35,000 $35,000

Other Costs of Sales $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0

Total Cost of Sales $35,000 $35,000 $35,000 $35,000 $35,000 $35,000 $35,000 $35,000 $35,000 $35,000 $35,000 $35,000

Gross Margin $15,000 $15,000 $15,000 $15,000 $15,000 $15,000 $15,000 $15,000 $15,000 $15,000 $15,000 $15,000

Gross Margin % 30.00% 30.00% 30.00% 30.00% 30.00% 30.00% 30.00% 30.00% 30.00% 30.00% 30.00% 30.00%

Expenses

Payroll $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0

Marketing/Promotion $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0

Depreciation $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0

Rent $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0

Utilities $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0

Insurance $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0

Payroll Taxes 15% $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0

Other $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0

Total Operating Expenses $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0

Profit Before Interest and Taxes $15,000 $15,000 $15,000 $15,000 $15,000 $15,000 $15,000 $15,000 $15,000 $15,000 $15,000 $15,000

EBITDA $15,000 $15,000 $15,000 $15,000 $15,000 $15,000 $15,000 $15,000 $15,000 $15,000 $15,000 $15,000

Interest Expense $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0

Taxes Incurred $4,500 $4,500 $4,500 $4,500 $4,500 $4,500 $4,500 $4,500 $4,500 $4,500 $4,500 $4,500

Net Profit $10,500 $10,500 $10,500 $10,500 $10,500 $10,500 $10,500 $10,500 $10,500 $10,500 $10,500 $10,500

Net Profit/Sales 21.00% 21.00% 21.00% 21.00% 21.00% 21.00% 21.00% 21.00% 21.00% 21.00% 21.00% 21.00%

Appendix

Page 4

Table: Cash Flow

Pro Forma Cash Flow


Cash Received

Cash from Operations

Cash Sales $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000

Subtotal Cash from Operations $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000

Additional Cash Received

Sales Tax, VAT, HST/GST Received 0.00% $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0

New Current Borrowing $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0

New Other Liabilities (interest-free) $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0

New Long-term Liabilities $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0

Sales of Other Current Assets $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0

Sales of Long-term Assets $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0

New Investment Received $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0

Subtotal Cash Received $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000

Expenditures Month 1 Month 2 Month 3 Month 4 Month 5 Month 6 Month 7 Month 8 Month 9 Month 10 Month 11 Month 12

Expenditures from Operations

Cash Spending $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0

Bill Payments $150 $4,500 $4,500 $4,500 $7,833 $101,167 $4,500 $7,833 $101,167 $4,500 $7,833 $101,167

Subtotal Spent on Operations $150 $4,500 $4,500 $4,500 $7,833 $101,167 $4,500 $7,833 $101,167 $4,500 $7,833 $101,167

Additional Cash Spent

Sales Tax, VAT, HST/GST Paid Out $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0

Principal Repayment of Current Borrowing $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0

Other Liabilities Principal Repayment $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0

Long-term Liabilities Principal Repayment $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0

Purchase Other Current Assets $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0

Purchase Long-term Assets $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0

Dividends $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0

Subtotal Cash Spent $150 $4,500 $4,500 $4,500 $7,833 $101,167 $4,500 $7,833 $101,167 $4,500 $7,833 $101,167

Net Cash Flow $49,850 $45,500 $45,500 $45,500 $42,167 ($51,167) $45,500 $42,167 ($51,167) $45,500 $42,167 ($51,167)

Cash Balance $149,850 $195,350 $240,850 $286,350 $328,517 $277,350 $322,850 $365,017 $313,850 $359,350 $401,517 $350,350

Appendix

Page 5

Table: Balance Sheet

Pro Forma Balance Sheet


Assets Starting Balances

Current Assets

Cash $100,000 $149,850 $195,350 $240,850 $286,350 $328,517 $277,350 $322,850 $365,017 $313,850 $359,350 $401,517 $350,350

Inventory $200,000 $165,000 $130,000 $95,000 $60,000 $125,000 $90,000 $55,000 $120,000 $85,000 $50,000 $115,000 $80,000

Other Current Assets $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0

Total Current Assets $300,000 $314,850 $325,350 $335,850 $346,350 $453,517 $367,350 $377,850 $485,017 $398,850 $409,350 $516,517 $430,350

Long-term Assets

Long-term Assets $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0

Accumulated Depreciation $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0

Total Long-term Assets $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0

Total Assets $300,000 $314,850 $325,350 $335,850 $346,350 $453,517 $367,350 $377,850 $485,017 $398,850 $409,350 $516,517 $430,350

Liabilities and Capital Month 1 Month 2 Month 3 Month 4 Month 5 Month 6 Month 7 Month 8 Month 9 Month 10 Month 11 Month 12

Current Liabilities

Accounts Payable $0 $4,350 $4,350 $4,350 $4,350 $101,017 $4,350 $4,350 $101,017 $4,350 $4,350 $101,017 $4,350

Current Borrowing $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0

Other Current Liabilities $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0

Subtotal Current Liabilities $0 $4,350 $4,350 $4,350 $4,350 $101,017 $4,350 $4,350 $101,017 $4,350 $4,350 $101,017 $4,350

Long-term Liabilities $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0

Total Liabilities $0 $4,350 $4,350 $4,350 $4,350 $101,017 $4,350 $4,350 $101,017 $4,350 $4,350 $101,017 $4,350

Paid-in Capital $365,000 $365,000 $365,000 $365,000 $365,000 $365,000 $365,000 $365,000 $365,000 $365,000 $365,000 $365,000 $365,000

Retained Earnings ($65,000) ($65,000) ($65,000) ($65,000) ($65,000) ($65,000) ($65,000) ($65,000) ($65,000) ($65,000) ($65,000) ($65,000) ($65,000)

Earnings $0 $10,500 $21,000 $31,500 $42,000 $52,500 $63,000 $73,500 $84,000 $94,500 $105,000 $115,500 $126,000

Total Capital $300,000 $310,500 $321,000 $331,500 $342,000 $352,500 $363,000 $373,500 $384,000 $394,500 $405,000 $415,500 $426,000

Total Liabilities and Capital $300,000 $314,850 $325,350 $335,850 $346,350 $453,517 $367,350 $377,850 $485,017 $398,850 $409,350 $516,517 $430,350

Net Worth $300,000 $310,500 $321,000 $331,500 $342,000 $352,500 $363,000 $373,500 $384,000 $394,500 $405,000 $415,500 $426,000

Documents

Asclep Pharma